Product Reports Resources Pricing Login Book a demo

Nykode Therapeutics

Biotech & Life Sciences · Oslo, Norway · Founded 2007 · IPO 2020

Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies

Valuation $77M
Revenue $453K
Power Law Unicorn$1–10B valuation tier
Knowledge graph
News Nykode raises NOK 286M in oversubscribed placement to push cancer trials forward Aug 27, 2026

Talent graph

Nykode Therapeutics's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Nykode Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
Sarsia Seed Management
Series B+ 5 investors entered at this stage
Inven2
University of Oslo
Research Council of Norway
Kreftforeningen
Oslo University Hospital

Ownership

Who owns Nykode Therapeutics

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).

9.2% RASMUSSENGRUPPEN AS

“Other / undisclosed” is the 46.2% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Nykode Therapeutics has talent and traffic

Workforce by country
6 countries with
team presence
🇳🇴 Norway81%
🇩🇰 Denmark14.5%
🇸🇪 Sweden2.8%
🇩🇪 Germany1.2%
🇺🇸 United States0.8%
Top 5 of 6 shown
Web traffic by country
3.8K monthly visits
across markets
🇳🇴 Norway65.8%
🇺🇸 United States18.4%
🇩🇰 Denmark13.2%
🇬🇧 United Kingdom2.6%
Top 4 markets shown

Patent intelligence

$17M patent portfolio · 5 active families

Estimated portfolio value
$17M
21.8% of market cap · 9× smaller than top peer Cellectis ($152M)
5 active patent families
Where Nykode Therapeutics innovates A-DNAAntigen-presenting cellCancer treatmentCancer vaccineCarcinosis

Where Nykode Therapeutics concentrates vs peers

Each axis is a top-10 topic across Nykode Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Nykode Therapeutics

An AI-synthesized read of the highest-engagement posts about Nykode Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nykode Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles